Hyperfine (HYPR) Competitors

Hyperfine (NASDAQ:HYPR) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Is HYPR or RXST more profitable?

RxSight has a net margin of -21.93% compared to Hyperfine's net margin of -364.54%. RxSight's return on equity of -11.56% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-364.54%	-78.47%	-65.00%
RxSight	-21.93%	-11.56%	-10.31%

Which has preferable earnings and valuation, HYPR or RXST?

RxSight has higher revenue and earnings than Hyperfine. RxSight is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$12.89M	8.30	-$40.72M	-$0.54	-2.55
RxSight	$139.93M	2.46	-$27.45M	-$0.80	-10.51

Which has more risk & volatility, HYPR or RXST?

Hyperfine has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.

Do analysts recommend HYPR or RXST?

Hyperfine presently has a consensus price target of $1.28, suggesting a potential downside of 6.67%. RxSight has a consensus price target of $10.00, suggesting a potential upside of 18.89%. Given RxSight's higher possible upside, analysts clearly believe RxSight is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
RxSight	2 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.91

Does the media favor HYPR or RXST?

In the previous week, RxSight had 37 more articles in the media than Hyperfine. MarketBeat recorded 49 mentions for RxSight and 12 mentions for Hyperfine. Hyperfine's average media sentiment score of 0.45 beat RxSight's score of -0.07 indicating that Hyperfine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RxSight	1 Very Positive mention(s)	3 Positive mention(s)	36 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in HYPR or RXST?

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 31.0% of Hyperfine shares are held by insiders. Comparatively, 9.6% of RxSight shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

RxSight beats Hyperfine on 9 of the 16 factors compared between the two stocks.